A Randomized, Double-blind, Placebo-controlled, Parallel, Trial to Determine the Safety and Efficacy of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
Latest Information Update: 06 Feb 2023
Price :
$35 *
At a glance
- Drugs Budesonide (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIROCCO-1
- Sponsors Aquilon Pharma
- 01 Feb 2023 Status changed from discontinued to completed.
- 09 Jan 2023 The trial has been discontinued in Belgium, according to European Clinical Trials Database record
- 05 Jan 2023 Status changed from recruiting to discontinued.